- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Ocrelizumab – July 2025
Ocrelizumab; Solution for subcutaneous injection 920 mg in 23 mL ; Ocrevus®
Last updated
9 July 2025